Sol-Gel Technologies announces reverse share split to increase market price and comply with Nasdaq.

From GlobeNewswire: 2025-05-01 07:00:00

Sol-Gel Technologies Ltd. announced a reverse share split of its Ordinary Shares at a ratio of 10-for-1 to increase the per share market price and comply with Nasdaq listing requirements. The Reverse Split will be effective on May 2, 2025, with trading expected to begin on May 5, 2025, under the symbol “SLGL.” Shareholders will automatically receive post-split shares, and fractional shares will be rounded. The Company’s pipeline includes FDA-approved treatments for acne and rosacea, as well as drug candidates for rare skin diseases. Additional information can be found in the proxy statement filed with the SEC on February 18, 2025. Sol-Gel, a pharmaceutical company, faces potential delays in regulatory milestones, lower revenue income, and increased expenses. These factors may impact the success of clinical trials and overall business objectives. The company’s financial resources, ability to find partners, obtain regulatory approvals, and protect intellectual property are crucial. Competition, market conditions, and geopolitical conflicts in Israel are additional challenges. Sol-Gel’s ability to navigate these factors will determine its future success. For more information, contact Chief Financial Officer Eyal Ben-Or at [email protected] or +972-8-9313429.



Read more at GlobeNewswire: Sol-Gel Announces Reverse Share Split